Downloads: 2 | Views: 128 | Weekly Hits: ⮙2 | Monthly Hits: ⮙2

Review Papers | Chemistry | India | Volume 12 Issue 5, May 2023 | Popularity: 4.9 / 10

Rate This Article!      

Benzothiazole Analogues: As Aldose Reductase Inhibitor (ARIs) for the Management of Diabetic Neuropathy and Cardiomyopathy

Rima Mahapatra, Kuntal Hazra

Abstract: Currently, 463 million people are suffering from diabetes globally, which is about 9.3% and it will be supposed to be increased to 578 million by 2030. Long-term suffering leads to other different complications associated with diabetes, among them diabetic polyneuropathy and cardiomyopathy are the most common. However, only one drug till now has passed phase-III clinical trials for the treatment of diabetic complications, namely Epalrestat, an aldose reductase inhibitor (ARIs) that is manufactured and marketed by Alfresa Pharma Corporation, Japan. So, research is going on for the finding of new drugs. ARIs can be the potent drug of choice for diabetic complications. The 3D structure of the aldose reductase enzyme was predicted by X-ray crystallography and the binding affinity towards the various new ARIs has been studied through molecular modeling and docking. The ARIs with a carboxylic group and a benzothiazole moiety always had shown better activity than the other derivatives. Lidorestat and zopalrestat are two ARIs currently in clinical trials.

Keywords: Diabetes, epalrestat, ARIs, carboxylic group, benzothiazole

Edition: Volume 12 Issue 5, May 2023

Pages: 1692 - 1696

DOI: https://www.doi.org/10.21275/SR23520191905

Make Sure to Disable the Pop-Up Blocker of Web Browser

Click to Cite this Article

Similar Articles